Traditional Chinese Medicine (TCM) has been used for thousands of years to treat human diseases. Recently, many databases have been devoted to studying TCM pharmacology. Most of these databases include information about the active ingredients of TCM herbs and their disease indications. These databases enable researchers to interrogate the mechanisms of action of TCM systematically. However, there is a need for comparative studies of these databases, as they are derived from various resources with different data processing methods. In this review, we provide a comprehensive analysis of the existing TCM databases. We found that the information complements each other by comparing herbs, ingredients, and herb-ingredient pairs in these databases. Therefore, data harmonization is vital to use all the available information fully. Moreover, different TCM databases may contain various annotation types for herbs or ingredients, notably for the chemical structure of ingredients, making it challenging to integrate data from them. We also highlight the latest TCM databases on symptoms or gene expressions, suggesting that using multi-omics data and advanced bioinformatics approaches may provide new insights for drug discovery in TCM. In summary, such a comparative study would help improve the understanding of data complexity that may ultimately motivate more efficient and more standardized strategies towards the digitalization of TCM.
Herbal medicines, particularly traditional Chinese medicines (TCMs), are a rich source of natural products with significant therapeutic potential. However, understanding their mechanisms of action is challenging due to the complexity of their multi-ingredient compositions. We introduced Herb-CMap, a multimodal fusion framework leveraging protein–protein interactions and herb-perturbed gene expression signatures. Utilizing a network-based heat diffusion algorithm, Herb-CMap creates a connectivity map linking herb perturbations to their therapeutic targets, thereby facilitating the prioritization of active ingredients. As a case study, we applied Herb-CMap to Suhuang antitussive capsule (Suhuang), a TCM formula used for treating cough variant asthma (CVA). Using in vivo rat models, our analysis established the transcriptomic signatures of Suhuang and identified its key compounds, such as quercetin and luteolin, and their target genes, including IL17A, PIK3CB, PIK3CD, AKT1, and TNF. These drug–target interactions inhibit the IL-17 signaling pathway and deactivate PI3K, AKT, and NF-κB, effectively reducing lung inflammation and alleviating CVA. The study demonstrates the efficacy of Herb-CMap in elucidating the molecular mechanisms of herbal medicines, offering valuable insights for advancing drug discovery in TCM.
Echinacea purpurea (L.) Moench (EP) is a well-known botanical supplement with antioxidant characteristics. However, the effects of EP on oxidative stress induced by hyperthyroidism have not yet been studied. This study was designed to evaluate the antioxidative effect of ethanolic Echinacea Purpurea (EEP) on hyperthyroidism-induced oxidative stress mice using an integrated strategy combining transcriptomics with network pharmacology analysis. Firstly, a hyperthyroidism mice model was induced via thyroxine (160 mg/kg) and EEP (1, 2, or 4 g/kg) once daily for 2 weeks. Body weight, thyroid-stimulating hormones, and oxidative stress markers were tested. Secondly, EEP regulating the potential genes at transcript level were analyzed. Thirdly, a network pharmacology based on the constituents of EEP identified using UPLC-Q-TOF-MS analysis was adopted. Finally, a joint analysis was performed to identify the key pathway. The results showed that EEP significantly changed the thyroid-stimulating hormones and oxidative stress markers. Meanwhile, RT-qPCR and Western Blotting demonstrated that the mechanism of the antioxidant effect of EEP reversed the mRNA expression of EHHADH, HMGCR and SLC27A2 and the protein expression of FABP and HMGCR in AMPK and PPAR signaling pathways. This study integrates transcriptomics with network pharmacology to reveal the mechanism of ameliorative effect of EEP on hyperthyroidism-induced oxidative stress.
Herbal medicine is a valuable resource for disease treatment, with enhanced synergistic efficacy and fewer side effects through combined herbal formulations. However, the synergistic mechanisms of action (MOAs) of these herbal medicines remain largely unexplored. Given the complexity of herbal systems, it is impractical to evaluate all possible drug/ingredient pairs experimentally. In this study, we propose a network-based model, HerbSyner_Finder, to prioritize synergistic ingredients in herbal medicine. By integrating network proximity and community analyses, HerbSyner_Finder could construct a multidimensional combinatorial atlas for complex biological systems to quantify herb-disease, ingredient-disease, herb-herb, and ingredient-ingredient interactions. Using cough variant asthma (CVA)-related herbal formulae as examples, kaempferol-quercetin and berberine-luteolin were successfully prioritized as synergistic for CVA among thousands of potential pairs. Further network analysis revealed that berberine and luteolin synergistically modulate the NLRP3/NF-κB signaling pathway, thereby alleviating CVA-associated inflammation. In summary, HerbSyner_Finder offers a tailored computational framework that efficiently identifies synergistic compounds from complex systems, and herbal medicines through high-throughput screening.
1 January 2025 in Computational and Structural Biotechnology Journal
Drug combinations have gained increasing interest due to their potential for optimal efficacy and for overcoming drug resistance. Herbal medicine is a complex system with multiple ingredients and has illustrated apparent therapeutic effects through thousands of years of clinical experience, offering a rich resource for combinational therapies. However, the underlying mechanisms of their synergistic therapeutic effects in disease treatment remain obscure for most herbal medicines. To fill this gap, we developed an integrated database, HerbComb (https://herbcomb.com/), to discover combinatorial therapies in herbal medicine, featuring three unique functions: drug prepositioning, customized combinatorial analysis, and biological and pharmacological features. Additionally, transcriptional gene signatures and ADMET properties were also interrogated as interactive functionalities to facilitate combinational analysis. Using Tongxinluo for Stroke as a case study, we identified and validated Oleanolic acid and Ferulic acid as synergistic ingredients. In summary, HerbComb is a versatile data exploration platform designed to characterize synergistic interactions among herbal medicines, enhance understanding of synergistic mechanisms, and facilitate the discovery of effective drug combinations.
Acute myeloid leukemia (AML) is a clonal malignancy of myeloid progenitor cells that demonstrates highly variable responses to current regimens, highlighting the need for precision medicine. However, reliable biomarkers for precision medicine treatment remain elusive due to cellular heterogeneity. Conventional Models based on bulk RNA sequencing and ex vivo assays often fail to capture the intricate molecular pathways and gene networks that underlie treatment response and resistance. Here, NetAML, a novel network‐based precision medicine platform that systematically develops 87 drug sensitivity prediction models for 87 clinical drugs using ex vivo drug responses from 520 AML patients with RNA‐Seq is presented. The approach leverages network‐based analysis and machine learning to identify biologically interpretable gene signatures that capture the complex molecular interactions driving differential drug responses. Notably, the signature genes derived from the models reveal distinct cellular mechanisms. For instance, the co‐expression of C19ORF59 and FLT3 is associated with resistance to FLT3 inhibitors. In summary, NetAML offers a powerful strategy for personalized AML treatment by constructing drug‐specific models, identifying clinically actionable biomarkers, and supporting the development of optimized, patient‐specific therapeutic regimens.